Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...

An overview of the top 10 stories from Optometry Times in 2025.

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Regeneron has had its hands full this year contending with regulatory setbacks, Amgen's marketed Eylea biosimilar and Roche's hard-charging ophthalmology rival Vabysmo. Next year, the biosimilar ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence ...